Rivaroxaban now FDA approved for prevention/treatment of PE/DVT

The FDA has extended approval for rivaroxaban to include the prevention and treatment of PE/DVT. It has been previously approved for prevention of VTE after hip/knee surgery, and prevention of Afib-associated stroke (FDA site).

Danielle Scheurer

Dr. Scheurer is a clinical hospitalist and the Medical Director of Quality and Safety at the Medical University of South Carolina in Charleston, South Carolina, and is Assistant Professor of Medicine. She is a graduate of the University of Tennessee College of Medicine, completed her residency at Duke University, and completed her Masters in Clinical Research at the Medical University of South Carolina. She also serves as the Web Editor and Physician Advisor for the Society of Hospital Medicine.

Leave a Comment